Senior Investigator, National Cancer Institute, Center for Cancer ResearchBiography
Dr. Neckers received his Ph.D. from the University of Connecticut, completed postdoctoral training at the NIH, and joined the NCI in 1981. He became Chief of the Tumor Cell Biology Section, Medicine Branch, in 1988. An early proponent of translational research, Dr. Neckers pioneered development of oligonucleotide-based therapeutic strategies. Recently, Dr. Neckers has been investigating the role of chaperone proteins in signal transduction. His identification of benzoquinone ansamycins as specific antagonists of the chaperone HSP90 uncovered the importance of this protein for the growth and survival of cancer cells and led directly to the first phase I clinical trial of an HSP90 antagonist as an anticancer agent. Dr. Neckers continues to examine the pivotal role of Hsp90 in cancer cell survival, and participates in the ongoing translational development of Hsp90 inhibitors as novel anti-cancer agents. Dr. Neckers holds several patents and has been the recipient of several NIH Merit and NIH Inventor's Awards.